NEWS: OCTOBER 2004

-10/22/2004-

Eli Lilly to close facility in RTP and cut 1,000 jobs. To read article click here.

Rhodia SA to cut 189 jobs at its French organic chemicals operations. To read article click here.

Kinexus Bioinformatics Corporation launches its sixth Kinetworks Phospho-Site Screening Service, KPSS 6.0. To read article click here.

The United Kingdom's highest court revokes key drugs patent held by Amgen in favor of Transkaryotic Therapies Inc. To read article click here.

Syrrx Inc. publishes the atomic structure of c-Kit kinase in complex with Novartis' cancer drug Gleevec® (STI-571). To read article click here.

Scientists publish in the October 29 issue of the Journal of Biological Chemistry new protein named PICT-1 is involved in the regulation of PTEN, the second most commonly mutated tumor suppressor in human tumors. To read article click here.

-10/21/2004-

Press Release: IBC Life Sciences: Chemists and Biologists Collaborate on Advances in Drug Discovery. To read press release click here.

Roche scientists publish in the October 22 issue of Science novel computational method to detect disease-causing genes. To read article click here.

MedImmune initiates intranasal vs injectable flu vaccine Phase III clinical trials. To read article click here.

AtheroGenics Inc.'s rheumatoid arthritis drug AGIX-4207 fails clinical trials and discontinues its development. To read article click here.

CytoGenix and Baylor College of Medicine form antibacterial research collaboration. To read article click here.

Alchemia Limited reveales new antibiotic drug technology by inhibiting transglycolase (TG) enzyme activity. To read article click here.

Merck & Co. and Arena Pharmaceuticals expand cardiovascular collaboration. To read article click here.

UC scientists identify new protein called MC4R plays key role in obesity. To read article click here.

Nobex Corporation and Biocon Limited form alliance to co-develop oral insulin treatment for diabetes. To read article click here.

Tata Consultancy Services and BioStrx form collaboration for the optimization of lead compounds. To read article click here.

CuraGen Corporation to cut a third of its workforce. To read article click here.

EntreMed Inc. receives US patent 6,805,865 entitled "Compositions and methods for treating cancer and hyperproliferative disorders". To read article click here.

MDL introduces the MDL® Patent Chemistry Database. To read article click here.

-10/20/2004-

Researchers develop High Throughput Infrared Immunostaining method for rapid and detailed evaluation of GPCR's in mouse brain. To read article click here.

Arena Pharmaceuticals Inc. and Merck & Co. Inc. extend cardiovascular research collaboration until October 2007. To read article click here.

Norak Biosciences Inc. and Curis Inc. form research collaboration. To read article click here.

Introgen Therapeutics Inc. receives U.S. patent 6,805,858 entitled "Methods for the Administration of Adenovirus p53". To read article click here.

New study indicates that humans just have 20,000 to 25,000 genes. To read article click here.

-10/19/2004-

Press Release: ASINEX LTD. AND RECORDATI S.P.A. ANNOUNCE AN INTEGRATED DRUG DISCOVERY PROJECT. To read press release click here.

Press Release: Available from Tecan Europe the LabCD® reduces all of the requisite steps for a wide variety of separation and assay procedures from a macro to a micro scale integrating them into a single low-cost disposable device. To read press release click here.

Press Release: Guava Technologies, a leading supplier of integrated cellular analysis systems for life science research, has announced a new series of online seminars focusing upon CellHealth™ profiling and single cell analysis. To read press release click here.

BioCryst Pharmaceuticals Inc. initiates Phase I clinical trials of forodesine hydrochloride (BCX-1777) in refractory patients with cutaneous T-cell lymphoma. To read article click here.

GlaxoSmithKline ends partnership with Advancis Pharmaceuticals. To read article click here.

Exelixis Inc. completes the acquisition of X-Ceptor Therapeutics Inc. To read article click here.

Liponex Inc. receives U.S. patent allowance for its CRD5 drug for the treatment of cholesterol and atherosclerosis. To read article click here.

Insmed Incorporated to intiate clinical trials of small molecule IGF-IR tyrosine kinase inhibitor INSM-18 for prostate cancer. To read article click here.

Celera Diagnostics identifies genetic variants associated with late-onset Alzheimer's disease. To read article click here.

-10/18/2004-

Press Release: Frost & Sullivan: Increased Emphasis on Downstream Processing Key Trend in Biopharmaceuticals Market. To read press release click here.

Press Release: Genevac Ltd, leader in solvent evaporation technology, has announced a new line of sample holders for its popular EZ-2 solvent evaporator. The new holders are specifically designed to take a variety of round bottom flasks ranging from 25ml up to 500ml. To read press release click here.

Strategic Research Institute to host the 2nd Annual Phosphodiesterases in Drug Discovery & Development Conference in Philadelphia, November 8-9, 2004. To read article click here.

Maxim Pharmaceuticals to reduce its workforce by around 50%. To read article click here.

Pancreatic cell transplant cures patient of diabetes. To read article click here.

Neurologix Inc. receives U.S. patent 6,780,409 entitled "Glutamic acid decarboxylase (GAD) based delivery system." To read article click here.

Vertex Pharmaceuticals Phase IIa clinical trials indicates oral p38 MAP kinase inhibitor VX-702 to be effective. To read article click here.

-10/15/2004-

Press Release: The Metz Syn10 from Radleys Discovery Technologies offers truly versatile parallel synthesis with variable heating, cooling, refluxing and stirring. The Metz Syn10 will simultaneously carry out 10 reactions, each with a different temperature, from -30°C to +150°C. To read press release click here.

GlaxoSmithkline Biologicals’ RTS/AS02A malaria vaccine shows promising results in the largest childhood clinical trials in Africa. To read article click here.

FDA approves Roche and Trimeris Inc.'s fusion inhibitor Fuzeon® (enfuvirtide) for the treatment of HIV. To read article click here.

Pharmaceutica 's BTA19976a compound eliminates MRSA (methicillin-resistant Staphylococcus aureus) superbug's resistance to methicillin. To read article click here.

UC Davis opens $95 million state-of-the-art Genome and Giomedical Sciences Facility. To read article click here.

PPD and Syrrx Inc. submit NDA application to the FDA for a Syrrx-designed human dipeptidyl peptidase IV (DPP IV) inhibitor for the treatment of type II diabetes. To read article click here.

Human Genome Sciences initiates two Phase II clinical trials of its anticancer drug in advanced non-Hodgkin's lymphoma and colorectal cancer patients. To read article click here.

VistaGen Therapeutics and Sanwa Kagaku Kenkyusho form diabetes drug discovery collaboration. To read article click here.

-10/14/2004-

QTL Biosystems launches the QTL LightSpeed™ Kinase platform. To read article click here.

Diversa Corporation receives U.S. patent 6,790,605 entitled "Methods for obtaining a desired bioactivity or biomolecule using DNA libraries from an environmental source." To read article click here.

-10/13/2004-

Press Release: Genetix has announced the availability of issue 2 of Microarray News - a newsletter focusing on the latest technical advances and applications developments in microarraying. To read press release click here.

ArQule Inc. discovers series of potent orally active RAF kinase inhibitors. To read article click here.

Norak Biosciences Inc. and Purdue Pharma L.P. form G protein-coupled receptor (GPCR) based drug discovery collaboration. To read article click here.

EMD Biosciences Inc. releases several new Signal Transduction Interactive Pathways on its website. To read article click here.

-10/08/2004-

Press Release: Tecan Europe has launched Freedom EVO 75, a compact robotic pipetting system targeted at laboratories looking to automate medium throughput liquid handling procedures in genomics, proteomics and drug discovery applications. To read press release click here.

Press Release: INTEGRA Biosciences has announced a new version of their popular FIREBOY plus™ - a versatile mobile Bunsen burner incorporating a unique triple safety system. To read press release click here.

Biophage Pharma Inc. announces breaktrough in live bacteria quantification with nanosensor technology. To read article click here.

Johnson & Johnson warns that its rheumatoid arthritis drug Remicade may have a higher risk of lymphoma. To read article click here.

Odyssey Thera Inc. and Merck & Co. Inc. expand collaboration to elucidate the full spectrum of activity of selected Merck compounds in human cells. To read article click here.

-10/07/2004-

Peninsula Pharmaceuticals Inc. completes Phase I clinical trials of PPI-0903 for bacterial infections. To read article click here.

FDA puts on hold GenVec Inc.'s clinical trials of TNFerade for cancer. To read article click here.

Parker Hughes scientists publish in the September issue of the journal British Journal of Hematology specific BTK inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13) improves bone marrow transplantation outcome in mice. To read article click here.

AstraZeneca to delay for a year the launch of Galida for diabetes treatment. To read article click here.

ImClone Systems Inc. and Bristol-Myers Squibb to begin Phase III clinical trials of Erbitux for lung cancer treatment. To read article click here.

-10/06/2004-

EMD Biosciences Inc. releases the Calbiochem® Inhibitor SourceBook™. To read article click here.

Medicure Inc. announces positive results of its newest drug MC-45308 for the prevention of blood clots. To read article click here.

Scientists create genetic cattle DNA map. To read article click here.

Saqqara Consultants and Cellular Genomics Inc. form structural biology alliance. To read article click here.

Singapore researcher claims breakthrough in ovarian cancer detection. To read article click here.

Evotec OAI AG and ALTANA Pharma AG sign kinase drug discovery collaboration. To read article click here.

Merck & Co. Inc. to use Norak Biosciences Inc.'s Transfluor® technology for GPCR drug discovery. To read article click here.

FDA grants orphan drug designation to Medarex Inc.'s MDX-060 for the rreatment of Hodgkin's Disease. To read article click here.

MethylGene Inc. initiates Phase II clinical trials of MG98 for the treatment of metastatic renal cell cancer. To read article click here.

-10/05/2004-

Tripos Inc. releases SYBYL 7.0 Discovery Software Suite. To read article click here.

Neuro Discovery Inc. acquires Allon Therapeutics Inc. To read article click here.

Sigma-Aldrich and Rubicon Genomics sign genome amplification pact. To read article click here.

Artemis Pharmaceuticals GmbH and Boehringer Ingelheim from genomics collaboration. To read article click here.

FDA approves Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd.'s Abilify (aripiprazole) for the treatment of acute bipolar mania. To read article click here.

ZymoGenetics Inc. grants Novo Nordisk A/S exclusive worldwide rights to recombinant Factor XIII portfolio. To read article click here.

Merix Bioscience changes its name to Argos Therapeutics. To read article click here.

Ivax Corporation and Nippon Shinyaku to develop and market polo-like kinase inhibitor HMN-214 for the treatment of several cancers. To read article click here.

Genelabs Technologies Inc.'s drug Prestara fails clinical trials for lupus treatment. To read article click here.

FDA grants fast track designation to Medarex Inc.'s MDX-010 for the treatment of metastatic melanoma. To read article click here.

-10/04/2004-

Press Release: Guava Technologies Inc., a leading provider of complete solutions for easy-to-use on-demand cellular analysis, has announced the appointment of Gianfranco de Feo, Ph.D., to the position of director, Customer Support and Service. Dr. de Feo was previously associate director, Genomics Collaborations at Affymetrix Inc., in Santa Clara, California. To read press release click here.

Argenta Discovery Ltd. and Etiologics Ltd. merge. To read article click here.

Scientists in Singapore who are developing a SARS vaccine claim to have found a breakthrough in milk. To read article click here.

Adherex Technologies receives US patent 6,797,807 entitled "Compounds and Methods for Cancer Therapy”. To read article click here.

Telik Inc. announces positive data from a Phase 2 combination study of TELCYTA™ (TLK286) administered with Doxil®. To read article click here.

NIH Roadmap for medical research accelerates. To read article click here.

Affymax Inc. begins placebo controlled Phase I clinical trials of peptide-based Hematide™ to stimulate the production of red blood cells. To read article click here.

-10/01/2004-

SinusPharma Inc. initiates Phase I clinical trials of SPRC-AB01 for chronic rhinosinusitis treatment. To read article click here.

Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc. announce results from Phase II clinical trial of RAF kinase and VEGFR inhibitor BAY 43-9006 for liver cancer treatment. To read article click here.

Maxim Pharmaceuticals' anticancer agent MX2167 induces apoptosis by targeting the transferrin receptor in tumor models. To read article click here.

FDA approves Bristol-Myers Squibb Company's Abilify® (aripiprazole) for the treatment of acute bipolar mania. To read article click here.

Researchers publish in the October 8 issue of the Journal of Biological Chemistry evidence of a DNA sequence that causes the destabilization and decay of the protooncogene bcl-2 (B-cell lymphoma/leukemia-2). To read article click here.

Ivax Corp. and Nippon Shinyaku sign agreement to develop and market polo-like kinase inhibitor HMN-214 for cancer treatment. To read article click here.

Tapestry Pharmaceuticals Inc. announces its novel anticancer compound TPI-273 shows inhibitory activity in a variety of tumors. To read article click here.

Exelixis Inc. discloses pre-clinical data for its receptor tyrosine kinase (RTK) inhibitors XL647 and XL999. To read article click here.

Neuro Discovery Inc. acquires Allon Therapeutics Inc. To read article click here.